About Medpace Holdings, Inc. - Common Stock (MEDP)
Medpace Holdings Inc is a global contract research organization (CRO) that specializes in providing a range of services to the pharmaceutical and biotechnology industries. The company supports clients throughout the drug development process, offering expertise in clinical trials, regulatory compliance, and data management. Medpace focuses on delivering efficient and high-quality clinical services across various therapeutic areas, helping to streamline the path from clinical research to market approval. Through its integrated approach, the company aims to accelerate the development of new treatments while ensuring adherence to safety and regulatory standards. Read More
The Law Offices of Frank R. Cruz announces an investigation of Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Medpace Holdings Inc. (NASDAQ: MEDP) securities between April 22, 2025 and February 9, 2026. Medpace is a clinical contract research organization (CRO) focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026. Medpace describes itself as a “clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.”
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medpace (MEDP) To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options
The DJS Law Group reminds investors of a class action lawsuit against Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
LOS ANGELES, April 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...
Over the past six months, Medpace’s shares (currently trading at $483.21) have posted a disappointing 11.2% loss while the S&P 500 was down 5.5%. This might ...
Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance pro...
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development inputs & services stocks fared in Q4, starting with Medpace (NASDAQ:MEDP).
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medpace (MEDP) To Contact Him Directly To Discuss Their Options
Understanding the real drivers behind dramatic stock swings can help investors avoid costly mistakes and spot opportunities hidden beneath the headlines.
